Clonal origin of aminoglycoside-resistant *Citrobacter freundii* isolates in a Danish county

N. NØRSKOV-LAURITSEN*†, D. SANDVANG‡, J. HEDEGAARD§, V. FUSSING[, K. K. MORTENSEN§, H. U. SPERLING-PETERSEN§ and H. C. SCHÖNHEDER†*

*Department of Clinical Microbiology, Aalborg Hospital, DK-8000 Aalborg, †Department of Clinical Microbiology, Aarhus University Hospital, DK-8000 Aarhus C, ‡Danish Veterinary Laboratory, DK-1345 Kbh V, §Department of Molecular and Structural Biology, Aarhus University, DK-8000 Aarhus C, ||Department of Gastrointestinal Infections and #Clinical Microbiology, Statens Serum Institut, DK-2300 Copenhagen S, Denmark

During 1997, attention was drawn to an increased frequency of aminoglycoside-resistant *Citrobacter freundii* in a Danish county, when a total of 24 resistant *C. freundii* isolates was detected. In this study, 15 such isolates were typed by pulsed-field gel electrophoresis, ribotyping and partial sequencing of the gene encoding translation initiation factor 2. Fourteen of the 15 isolates were identical, as evaluated by their antibiograms and by all these typing methods. This epidemic strain harboured the aminoglycoside resistance genes *aac(3’)-II and ant(3’)-I*, with the latter located in tandem with a dihydrofolate reductase gene in a class I integron. The source of the strain remains unresolved. Representative isolates were obtained from various specimens from hospitals and general practice throughout the county, with no evidence of patient-to-patient transmission.

**Introduction**

A recommended and widely employed empirical treatment for community-acquired sepsis in Denmark consists of an aminoglycoside in combination with a β-lactam antibiotic (usually penicillin or ampicillin) plus metronidazole [1, 2]. Crucial to this strategy is a low frequency of aminoglycoside resistance among Enterobacteriaceae, which cause almost 50% of the bacteremic episodes [2].

Prospective surveillance of gentamicin-resistant enteric rods was initiated in the county of Northern Jutland, Denmark, in 1993. The most marked observation was a sudden increase of gentamicin-resistant isolates of *Citrobacter freundii*, from none in 1994 to 24 in 1997 [3]. *C. freundii* is a species of Enterobacteriaceae with some similarity to *Escherichia coli* and *Salmonella* spp., and DNA sequence analysis shows that *Citrobacter, Escherichia* and *Salmonella* form one distinct lineage within the Enterobacteriaceae [4]. Nevertheless, and in contrast to its relatives, *C. freundii* is rarely implicated in human diarrhoea and enteritis; rather, it is an opportunist pathogen that can cause a broad range of infections, the most common being those of the urinary tract. The species has a chromosomal class C (AmpC) β-lactamase that makes treatment outcomes with most cephalosporins unpredictable, and that confers ampicillin resistance [5].

Few suspected outbreaks of infection caused by *Citrobacter* spp. have been reported. However, in a case of vertical transmission of infections with *C. koseri*, the common identity of two isolates was demonstrated by pulsed-field gel electrophoresis (PFGE) and ribotyping [6], and in a nosocomial cluster of infections with *C. koseri* with extended-spectrum β-lactamases, six of eight isolates belonged to the same epidemic strain, as evaluated by ribotyping and arbitrarily-primed PCR [7].

Because of the restricted knowledge on the epidemiology of infection with *C. freundii*, this study aimed to characterise a sample of isolates from the suspected outbreak in Northern Jutland by three DNA-based methods.

**Materials and methods**

**Collection, identification and susceptibility testing**

The surveillance, identification and susceptibility testing of gentamicin-resistant enteric rods were described

Received 14 Aug. 2000; revised version accepted 8 Dec. 2000.

Corresponding author: Dr N. Nørskov-Lauritsen (e-mail: profl@as.s.j.a.dk).
previously [3]. The isolates were kept at –80°C in broth supplemented with glycerol 10% v/v. Species identification was initially performed with a commercial system (Crystal RSE, Becton-Dickinson, USA) that does not differentiate between the more recently described species in the C. freundii complex. On retrieval for the present study, the isolates were further characterised with respect to fermentation of sucrose, dulcitol and melibiose, utilisation of malonate, de-carboxylation of ornithine and production of indole [8]. Based on these supplementary tests, speciation as C. freundii was confirmed. The isolates expressed high-level resistance to gentamicin, with MICs >256 mg/L as determined with E-tests (AB-Biodisk, Solna, Sweden).

Macro-restriction fragment analysis by PFGE
PFGE was done according to a protocol designed for investigations of E. coli O157:H7 [9]. Total cellular DNA was digested with the restriction endonucleases SpeI or XbaI (Pharmacia Biotechnology, Uppsala, Sweden). Electrophoresis was run on a CHEF-DR II apparatus (BioRad, Richmond, CA, USA) at 6 V/cm for 22 h with an initial switch time of 1 s and a final switch time of 40 s.

Automated ribotyping
Ribotyping was performed with the RiboPrinter™, used as recommended by the manufacturer (Qualicon, Wilmington, DE, USA). Briefly, single colonies from a 24-h culture on blood (5%) agar were suspended in sample buffer and incubated at 80°C for 15 min. After addition of lysis solution, the samples were transferred to the RiboPrinter™. Further analysis, including EcoRI restriction of DNA, was performed automatically. The ribotype profiles were aligned according to the position of a molecular size standard.

infB sequencing
PCR amplification and partial sequencing of infB, the gene encoding the prokaryotic translation initiation factor IF2, were performed as described previously [4]. A 417-nucleotide segment was selected in all sequences and was used for analysis. This fragment encodes the amino acid positions 424–562 with reference to E. coli IF2-1 [10].

Amplification of resistance genes
Aminoglycoside resistance genes (nomenclature according to Shaw et al. [11]) aac(3)-II, aac(3)-IV, aac(6’)-I, ant(2’)-I, ant(3’)-I, aph(3’)-I and aph(3’)-II were amplified by PCR. Primers were chosen from the following sequences (GenBank accession numbers and position of nucleotides): X51534, 381–400 and 731–750; X01385, 311–330 and 919–938; X60321, 243–263 and 508–527; X04555, 1491–1510 and 1800–1819; D43625, 1407–1426 and 1916–1933; J01839, 1182–1202 and 1827–1851; and V00618, 200–222 and 725–746. A total of 28 amplification cycles was performed, each consisting of 94°C for 45 s, 61°C (55°C in the case of aac(3)-II or aph(3’)-II) for 45 s and 72°C for 1 min. The amplification products were electrophoresed on agarose 1% gels and visualised under UV light after staining with ethidium bromide. PCR amplification of class I integrons was performed with primers IntI-1 and qacE-D1-B, as described previously [12]. The amplification product of c. 2.2 kb from isolate AR1 was purified with a QIAquick kit (Qiagen, Hilden, Germany) and subjected to sequencing with the same primers as used for the PCR. The initial sequencing revealed the presence of dhfrXII (encoding a dihydrofolate reductase conferring resistance to trimethoprim [13]) in the 5’-end of the amplification product, and aac(3’)-I in the 3’-end. Final sequencing of the entire PCR product was performed with the internal primers intI-1-B and ant(3’)-I-1-B [12], AME 23-B [13] and dhfrXII-F [14]. The reaction conditions for sequencing were as described previously [12].

Culture collection and nucleotide sequence accession numbers
C. freundii isolates AR1 (CCUG42386) and AR9 (CCUG42385) have been deposited at the Culture Collection of Gothenburg University, Sweden. GenBank accession numbers were allocated as follows for infB sequences: AR1–8, AJ236707–AJ236714; AR9–15, AJ236716–AJ236722; ASC1–4, AJ236723–AJ236726; and ASC5–7, AJ236728–AJ236730. The accession number AF175203 was allocated for the nucleotide sequence of the integron class I of isolate AR1 containing dhfrXII, orfF and ant(3’)-I.

Results
A county-based monitoring programme during 1993–1998 disclosed 378 aminoglycoside-resistant Enterobacteriaceae, as reported elsewhere [3]. Forty-one (11%) were identified as C. freundii and their distribution over time was indicative of an epidemic (Fig. 1). During the first 2 years of surveillance, no aminoglycoside-resistant C. freundii (ARC) were found, but four isolates were found in 1995 and 1996, 24 in 1997 and nine in 1998. When the antibiotic-susceptibility profiles of the 41 isolates were compared, one frequent antiobiotic (antiobiotic type 1) was revealed comprising resistance to streptomycin, gentamicin, netilmicin, tobramycin, tetracycline, sulphonamides and trimethoprim, coupled with susceptibility to amikacin and extended-spectrum cephalosporins. Twenty-eight (68%) of the 41 isolates expressed this phenotype; 13 of them were identified during Sept. 1997 (Fig. 1).
These 28 isolates were from patients widely distributed in the county: five of them originated from specimens submitted by general practitioners, 13 from the referral hospital of the county and 10 from five different district hospitals. No association with particular medical specialties or specific hospital departments could be identified (Table 1 and data not shown).

The present study began early in 1998, when 15 of the aminoglycoside-resistant C. freundii from 1997 were chosen for further investigation. The study group comprised the first isolate expressing the antibiogram type 1, the only aminoglycoside-resistant C. freundii with a different antibiogram type collected in 1997 (ARC9) and 13 other initial isolates with antibiogram type 1. Seven isolates without resistance to aminoglycosides (ASC) were included as controls. Four of these were selected from among blood culture isolates collected in 1997 and three from urine specimens. Epidemiological data for the 22 isolates are shown in Table 1.

### Typing of C. freundii

PFGE typing of the 22 isolates revealed eight different profiles (Fig. 2). The 14 resistant isolates of antibiogram type 1 all belonged to the same PFGE type, whereas ARC9, the only gentamicin-resistant isolate susceptible to streptomycin, gave a unique PFGE type. Among the seven aminoglycoside-susceptible organisms, six unique PFGE types were obtained, whereas one susceptible isolate, ASC5, gave the same PFGE type as did resistant isolates of antibiogram type 1 (Fig. 2). Identical conclusions were reached when DNA was restricted with SpeI (Fig. 2) or XbaI (data not shown).

The typing obtained with the Riboprint™ (Fig. 3) correlated well with the PFGE results, dividing the 22 isolates into seven ribogroups; nevertheless, two aminoglycoside-susceptible isolates, ASC3 and ASC7, were discriminated by PFGE (Fig. 2) but not by riboprinting (Fig. 3).

In a previous study on the phylogeny of Enterobacter-

### Table 1. C. freundii isolates investigated in the study

<table>
<thead>
<tr>
<th>Isolate</th>
<th>Month/year</th>
<th>Specimen</th>
<th>Institution*</th>
<th>Antibiogram</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARC1</td>
<td>7/97</td>
<td>Urine</td>
<td>Rmed1</td>
<td>1</td>
</tr>
<tr>
<td>ARC2</td>
<td>8/97</td>
<td>Urine</td>
<td>Dsur</td>
<td>1</td>
</tr>
<tr>
<td>ARC3</td>
<td>9/97</td>
<td>Tissue</td>
<td>Rmed2</td>
<td>1</td>
</tr>
<tr>
<td>ARC4</td>
<td>9/97</td>
<td>Urine</td>
<td>GP1</td>
<td>1</td>
</tr>
<tr>
<td>ARC5</td>
<td>9/97</td>
<td>Urine</td>
<td>D2med1</td>
<td>1</td>
</tr>
<tr>
<td>ARC6</td>
<td>9/97</td>
<td>Urine</td>
<td>GP2</td>
<td>1</td>
</tr>
<tr>
<td>ARC8</td>
<td>9/97</td>
<td>Urine</td>
<td>Rmed3</td>
<td>1</td>
</tr>
<tr>
<td>ARC9</td>
<td>10/97</td>
<td>Sputum</td>
<td>Recu</td>
<td>2</td>
</tr>
<tr>
<td>ARC10</td>
<td>10/97</td>
<td>Urine</td>
<td>Rmed4</td>
<td>1</td>
</tr>
<tr>
<td>ARC11</td>
<td>10/97</td>
<td>Wound</td>
<td>GP3</td>
<td>1</td>
</tr>
<tr>
<td>ARC12</td>
<td>10/97</td>
<td>Urine</td>
<td>Rsur2</td>
<td>1</td>
</tr>
<tr>
<td>ARC13</td>
<td>11/97</td>
<td>Urine</td>
<td>Rmed5</td>
<td>1</td>
</tr>
<tr>
<td>ARC14</td>
<td>11/97</td>
<td>Urine</td>
<td>D3med</td>
<td>1</td>
</tr>
<tr>
<td>ARC15</td>
<td>12/97</td>
<td>Bile</td>
<td>D3sur</td>
<td>1</td>
</tr>
<tr>
<td>ASC1</td>
<td>10/96</td>
<td>Blood1</td>
<td>Rsur2</td>
<td>wt</td>
</tr>
<tr>
<td>ASC2</td>
<td>6/97</td>
<td>Blood1</td>
<td>Rsur3</td>
<td>wt</td>
</tr>
<tr>
<td>ASC3</td>
<td>9/97</td>
<td>Blood1</td>
<td>Rmed4</td>
<td>wt</td>
</tr>
<tr>
<td>ASC4</td>
<td>3/98</td>
<td>Blood1</td>
<td>Rmed1</td>
<td>wt</td>
</tr>
<tr>
<td>ASC5</td>
<td>9/98</td>
<td>Urine</td>
<td>D3med</td>
<td>wt</td>
</tr>
<tr>
<td>ASC6</td>
<td>9/98</td>
<td>Urine</td>
<td>Rmed2</td>
<td>wt</td>
</tr>
<tr>
<td>ASC7</td>
<td>9/98</td>
<td>Urine</td>
<td>D2med2</td>
<td>wt</td>
</tr>
</tbody>
</table>

*Referring institution: GP, general practitioner; D, district hospital; R, referral hospital; med, medical department; sur, surgical department; icu, intensive care unit; reh, rehabilitation facility.

**Antibiotic susceptibility: wt, wild type susceptible to all aminoglycosides; 1, resistant to gentamicin, streptomycin, tobramycin, netilmicin, and susceptible to amikacin; 2, resistant to gentamicin, tobramycin, netilmicin, and susceptible to streptomycin and amikacin.

The suspected underlying diseases of the bacteremic patients were urinary tract infection, cholecystitis, renal abscess and leukaemia.
Aminoacyl synthetase 3-like activity

Fig. 2. PFGE DNA patterns of C. freundii obtained after restriction with SpeI. Lane m, λ mol. wt standards (kb).

Fig. 3. RiboPrint results for 22 isolates of C. freundii. The mol. wt is indicated at the top. Normalised data are shown for all the organisms, sorted by RiboPrint similarity.

found at the third-base sites of codons in 10 separate positions, giving rise to four sequence groups (Table 2).

Aminoglycoside resistance

To examine the genetic basis of aminoglycoside resistance of ARC1 (as a representative of the epidemic antibiotic type I strain) and ARC9, amplification of the genes for six aminoglycoside-modifying enzymes was attempted by PCR. Both isolates were positive for 3′-I. Isolate ARC1 also harboured ant(3′)-I. These genotypes were in agreement with the phenotypic expression of resistance, with gentamicin, netilmicin and tobramycin being susceptible to inactivation by AAC(3)-II, and streptomycin to ANT(3′)-I (11).

Gene cassettes – mobile elements normally found integrated at a specific site in an integron may be consecutively inserted in multi-cassette arrays (15). The 3′ conserved sequence of class I integrons contains a gene (sulI) conferring resistance to sulphonamides. Observation of sulphonamide resistance therefore prompted a search for gene cassettes associated with class I integrons in the multiresistant epidemic strain. PCR-amplification of DNA from isolate ARC1 revealed the presence of a class I integron with an inserted sequence of ~1700 bp. Sequencing of the amplification product revealed three open reading frames located in the integron (5′–3′). These comprised dhfrIII, conferring resistance to trimethoprim, orfP (320 bp) of unknown function (14) and ant(3′)-I (nucleotide sequence accession no. AF175203).

Discussion

Attention was drawn to a sudden increase in the prevalence of gentamicin resistance among clinical isolates of C. freundii in a Danish county. To examine a possible clonal relationship among these bacteria, 15 isolates were characterised by three DNA-based typing methods. The discriminatory power varied with the methods, but identical conclusions were reached. Of 15 resistant isolates investigated, 14 were identical when evaluated by typing methods, antibiotic susceptibility and biochemical characteristics. It is generally agreed that isolates indistinguishable by typing schemes, and sharing characteristics that distinguish them from epidemiologically unrelated strains, constitute a cluster, or clone, arising from a common precursor (16).
conclude that 14 of 15 resistant isolates investigated belonged to the same epidemic strain and will refer to this as a clone.

Based on antibiotic susceptibility, this clone may account for 28 of 41 aminoglycoside-resistant _C. freundii_ isolated in the county from 1993 to 1998. All of these were identified during an 18-month period (Fig. 1). A total of 160 patients in the county had a first-time isolate of _C. freundii_ during this 18-month period, and during this period the resistant clone thus accounted for 18% of isolates of this genus.

The clone expressed resistance to several antimicrobial agents, and the genes for resistance to trimethoprim, streptomycin and sulphonamides were transcribed from the same promozer in a class 1 integron. Class 1 integrons are prevalent among Enterobacteriaceae from various geographic locations, and the presence of a class 1 integron is statistically linked to aminoglycoside resistance [17–19]. _bfrIII_ was originally described within the same array of gene cassettes in a class 1 integron from an _E. coli_ isolated in Finland [14]. The deposited sequence from the Finnish isolate (nucleotide sequence accession no. Z21672) is 99.6% identical with the sequence obtained from ARC1 (data not shown; alignment based on 1087 bp).

The genes conferring resistance to gentamicin (aac(3)-II) and tetracycline may have been acquired together with the integron; an almost identical integron described previously was borne on a Tn21-like transposon, and resistance to chloramphenicol and ampicillin was co-transferred together with the integron-determined resistance [14].

One isolate without acquired resistance—ASC5, isolated 12 months after the peak incidence of the epidemic strain—was indistinguishable from the epidemic strain by all typing methods; it may be related to the epidemic strain before acquisition of resistance genes, or it may represent the strain after these genes had been lost.

The source of the outbreak strain remains unresolved. We were unable to trace any sign of cross-infection among patients, and although the majority of repre-

Table 2. Polymorphic nucleotide sites in a 417-bp segment of the infB gene sequence from 22 _C. freundii_ isolates

<table>
<thead>
<tr>
<th>Nucleotide position</th>
<th>1398</th>
<th>1410</th>
<th>1431</th>
<th>1437</th>
<th>1467</th>
<th>1473</th>
<th>1521</th>
<th>1587</th>
<th>1629</th>
<th>1638</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>T</td>
<td>A</td>
<td>A</td>
<td>C</td>
<td>G</td>
<td>G</td>
<td>G</td>
<td>A</td>
<td>G</td>
<td>C</td>
</tr>
<tr>
<td>II</td>
<td>–</td>
<td>–</td>
<td>G</td>
<td>–</td>
<td>A</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>III</td>
<td>A</td>
<td>G</td>
<td>T</td>
<td>A</td>
<td>–</td>
<td>G</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>IV</td>
<td>–</td>
<td>T</td>
<td>G</td>
<td>T</td>
<td>A</td>
<td>–</td>
<td>A</td>
<td>G</td>
<td>A</td>
<td>T</td>
</tr>
</tbody>
</table>

The nucleotide numbering is with reference to _E. coli_ [10]. Sequence group I encompasses all aminoglycoside-resistant _C. freundii_ of antibiotic type 1, as well as ASC2 and ASC5. The remaining five susceptible isolates constitute sequence groups II (ASC3, 6, 7) and III (ASC1, 4). The nucleotide sequence of group IV is unique to ARC9.

References